Company intelligence / Profile preview

Wilson Wolf

Saint Paul, Minnesota, USAwilsonwolf.com ↗

Ownership: Private
Employees: ~34
Development stage: Commercial

Overview

The G-Rex platform enables cost-effective, scalable production of immune cells for cell and gene therapies. It supports the manufacture of TILs, NK cells, LCLs with superior performance to traditional growth bags. Used by over 800 CGT entities globally. No direct clinical results as a therapeutic developer.

Modalities: DevicePlatform technology for cell therapy manufacturing
Industry: Therapeutic Medical Devices

Partnerships

Bio-TechneFresenius KabiScaleReady joint venture partner

Beyond the preview

Go deeper on Wilson Wolf.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Wilson Wolf.

Explore the full profile